Immunotherapy: Open Access
Open Access

Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK

Biography

Translational Pathology UK lead at AstraZeneca. Early Stage Translational Pathology Group Lead,May 2019 - Present2 years 5 months,Cambridge, United Kingdom. 
Senior Scientist,Mar 2015 - May 20194 years 3 months. 

Translational Scientist.Fahy Gurteen UK Limited,May 2013 - Feb 20151 year 10 months

Publications

• Research   
  Multiplex Immunohistochemistry: The Importance of Staining Order When Producing a Validated Protocol
  Author(s): Jihad Syed, Jack Ashton, Jesuchristopher Joseph, Gemma N Jones, Christian Slater, Alan Sharpe, Garry Ashton, William Howat, Richard Byers and Helen K Angell*
  
  Aim: The complexity of multifactorial diseases, such as cancer, poses significant challenges to the development of personalised therapies. Integrated digital histological analysis of tumours provides a better understanding of the immune microenvironment and the prognostic relationship associated with the enumeration and distribution of specific tumour infiltrating lymphocyte (TILs) subpopulations. To this effect multiplex cell labelling , alongside multi-spectral imaging (MSI) is an approach increasingly used to achieve more accurate in-situ TIL phenotyping and quantification. However, these approaches require full validation prior to utilisation , which is the fundamental aim of this study. Methods: Whole sections and tissue microarrays of lymphocyte-rich tissue were used to develop and validate a multiplex immunofluorescence (IF) protocol .. View More»
  

  Abstract HTML PDF